Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) and CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Valuation and Earnings
This table compares Syndax Pharmaceuticals and CNS Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Syndax Pharmaceuticals | $23.68 million | 57.26 | -$318.76 million | ($3.89) | -4.05 |
| CNS Pharmaceuticals | N/A | N/A | -$14.86 million | ($3,748.50) | 0.00 |
Profitability
This table compares Syndax Pharmaceuticals and CNS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Syndax Pharmaceuticals | -428.48% | -130.47% | -56.12% |
| CNS Pharmaceuticals | N/A | -226.23% | -155.31% |
Insider and Institutional Ownership
14.0% of CNS Pharmaceuticals shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for Syndax Pharmaceuticals and CNS Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Syndax Pharmaceuticals | 0 | 1 | 8 | 1 | 3.00 |
| CNS Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
Syndax Pharmaceuticals currently has a consensus price target of $38.00, indicating a potential upside of 141.42%. CNS Pharmaceuticals has a consensus price target of $300.00, indicating a potential upside of 5,793.91%. Given CNS Pharmaceuticals’ higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Syndax Pharmaceuticals.
Risk & Volatility
Syndax Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500.
Summary
Syndax Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
